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Formation and Degradation of Beta-
casomorphins in Dairy Processing
DUC DOAN NGUYEN,1 STUART KEITH JOHNSON,1 FRANCESCO BUSETTI,2 and
VICKY ANN SOLAH1
1Food Science and Technology Program, School of Public Health, Curtin Health Innovation Research Institute,
Curtin University, Perth, Western Australia, Australia
2Curtin Water Quality Research Centre, Department of Chemistry, Curtin University, Perth, Western Australia,
Australia
Milk proteins including casein are sources of peptides with bioactivity. One of these peptides is beta-casomorphin (BCM)
which belongs to a group of opioid peptides formed from b-casein variants. Beta-casomorphin 7 (BCM7) has been
demonstrated to be enzymatically released from the A1 or B b-casein variant. Epidemiological evidence suggests the
peptide BCM 7 is a risk factor for development of human diseases, including increased risk of type 1 diabetes and
cardiovascular diseases but this has not been thoroughly substantiated by research studies. High performance liquid
chromatography coupled to UV-Vis and mass spectrometry detection as well as enzyme–linked immunosorbent assay
(ELISA) has been used to analyze BCMs in dairy products. BCMs have been detected in raw cow’s milk and human milk
and a variety of commercial cheeses, but their presence has yet to be confirmed in commercial yoghurts. The finding that
BCMs are present in cheese suggests they could also form in yoghurt, but be degraded during yoghurt processing. Whether
BCMs do form in yoghurt and the amount of BCM forming or degrading at different processing steps needs further
investigation and possibly will depend on the heat treatment and fermentation process used, but it remains an intriguing
unknown.
Keywords Beta-casomorphin, cheese, yoghurt, heat treatment, fermentation, ripening
INTRODUCTION
Milk protein is a source of peptides that are bioactive
(Rizzello et al., 2005) including: angiotensin-converting
enzyme inhibitory (ACE-I) activity (Minervini et al., 2003;
Donkor et al., 2007); antihypertensive activity (Muguerza
et al., 2006), antibacterial activity (Minervini et al., 2003),
and opioid activity (De Noni and Cattaneo, 2010). The term
“opioid” is used for substances having morphine-like activity
that act by binding to opioid receptors. Opioid substances are
found in the center nervous system and the gastrointestinal
tract. These peptides play a crucial role in the response to pain
and stress (Kaminski et al., 2007).
Beta-casomorphins (BCMs) are a group of peptides with
opioid properties and are formed from proteolytic digestion of
b-casein (De Noni and Cattaneo, 2010). Among these pepti-
des, only beta-casomorphin 7 (BCM7) has been widely stud-
ied. The release of BCM7 during hydrolysis of b-casein
depends on the b-casein variant containing a histidine residue
at position 67. In recent years, epidemiological evidence has
indicated that consumption of milk containing the A1 variant
is linked to increased risk of type 1 diabetes and heart disease
(Elliott et al., 1999; McLachlan, 2001; Laugesen and Elliott,
2003). The European Food Safety Authority (EFSA) con-
cluded there was insufficient data to determine a causal rela-
tionship between BCM7 exposure and non-communicable
diseases (EFSA, 2009). Nevertheless the presence of these
peptides in dairy products needs further research due to their
putative link to elevated chronic disease risk.
The BCM7 peptide has been identified in raw milk
(Cieslinska et al., 2007; Cieslinska et al., 2012) and some
cheeses (Jarmolowska et al., 1999; De Noni and Cattaneo,
2010), but was not found in commercial yoghurt (Kahala
et al., 1993; Schieber and Br€uckner, 2000; De Noni and Catta-
neo, 2010). Whether BCMs do form and the amount of BCM
forming at different processing steps needs further
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investigation and possibly will depend on the heat treatment
and fermentation process but remains an intriguing unknown.
Analytical trends in the analysis of BCMs indicate reverse
phase high performance liquid chromatography (RP-HPLC) as
the preferred choice for separation of these polar, nonvolatile
peptides in a variety of dairy products. For detection, UV-Vis
absorbance has been widely used in a number of analytical
laboratories around the world (Muehlenkamp and Warthesen,
1996). Nowadays, at the forefront of detection techniques, is
mass spectrometry coupled to electrospray ionization (ESI)
which is by far the most reliable detection technique for small
peptides (De Noni and Cattaneo, 2010). Alternatively,
enzyme–linked immunosorbent assay (ELISA) has been
applied to detect and quantify BCMs in dairy products (Sien-
kiewicz-Sz»apka et al., 2009; Cieslinska et al., 2012).
This review aims to bring together the current knowledge on
BCMs, analyzing their possible sources and presence in dairy
products such as milk, cheese, and yogurt. The impacts of proc-
essing conditions such as thermal treatment, fermentation, and
cross link on formation and degradation of BCMs in dairy prod-
ucts are also discussed. Finally, the advantages and limitations
of each analytical technique currently in use to identify and
quantify BCMs are also reported along with some examples of
applications taken from the current scientific literature.
SOURCES OF BETA-CASOMORPHINS
Protein in bovine milk contains four caseins as1, as2, b, and
k-casein and two major whey proteins, b-lactoglobulin and
a-lactoalbumin (Kaminski et al., 2007). In recent years, the
209 amino acid residues in the chains of b-casein (Fig. 1)
(Swaigood, 2003; Truswell, 2005) have been studied exten-
sively. It was found that there are 13 variants present in bovine
milk including A1, A2, A3, A4, B, C, D, E, F, H1, H2, I, and
H (Kaminski et al., 2007), of which A1 and A2 are the most
common variants. The primary structure of some variants
is showed at Figure 1. Milk from European breeds such as
Holstein–Friesian mainly contains A1 b-casein (Tailford et al.,
2003), while A2 b-casein is commonly detected in milk from
Guernsey and Jersey breeds (Bell et al., 2006; Merriman,
2009). The difference between A1 and A2 variant is a single
amino acid at position 67 on the chain; being histidine in A1
and proline in A2 (Truswell, 2005; Kaminski et al., 2007).
Interestingly, this structural difference leads to different
properties when the two b-casein variants are hydrolyzed in
the intestine. According to Jinsmaa and Yoshikawa (1999), the
peptide bond between proline and isoleucine in the A2 variant
has more enzymatic resistance than that between histidine and
isoleucine in the A1 variant. So A1 b-casein is more easily
hydrolyzed at this residue by gastrointestinal enzymes, result-
ing in the release of BCM7 (Jinsmaa and Yoshikawa, 1999).
Consequently, BCM7 is liberated in the digestive tract from
b-caseins containing histidine residue at 67 position, including
A1 as well as B b-casein (Figure 2).
BCMs are a group of structurally similar peptides (Table 1)
with a sequence of 4–11 amino acids (Kaminski et al., 2007).
All BCMs have the same sequence for the first three amino
acids, tyrosine, proline, and phenylalanine (Muehlenkamp and
Warthesen, 1996), and have been identified in and isolated
from bovine milk (Kaminski et al., 2007; EFSA, 2009). These
peptides are released from b-casein at position 60 which is the
tyrosine residue and the other residues are released from other
positions (table 1) if the conditions are right.
PRESENCE OF BETA-CASOMORPHINS IN DAIRY
PRODUCTS
Milk
Bovine milk is a crucial food for humans as a source not
only of high quality protein, fat, minerals, and vitamins (Bell
et al., 2006; Kaminski et al., 2007; Nagpal et al., 2011), but
also of bioactive peptides that are linked to positive health
effects on the cardiovascular, nervous, and gastrointestinal
systems (Choi et al., 2012). Consumption of milk and dairy
products may play an important role for prevention of a num-
ber of diseases such as hypertension (Jauhiainen and Korpela,
2007), osteoporosis (Uenishi, 2006), obesity (Jaffiol, 2008),
dental decay (Shimazaki et al., 2008) and cardiovascular dis-
ease (Elwood et al., 2004a, 2004b; Elwood, 2005; Elwood
et al., 2005). In addition, bovine milk also contains peptides
with opioid properties, for instance BCM7 that may increase
risk of chronic disease (Cieslinska et al., 2007; Cieslinska
Figure 1. The primary structure of b-casein A2 indicating amino acid sub-
stitution of the variants (adapted from Swaigood, 2003).

































et al., 2012). Epidemiologically, however, intake of milk con-
taining A1 b-casein strongly correlates with ischemic heart
disease (McLachlan, 2001; Laugesen and Elliott, 2003) and
type 1 diabetes (Elliott et al., 1999; McLachlan, 2001; Birgis-
dottir et al., 2006). This implies that BCM7 released from
A1-b casein may be a significant contributor to the risk of car-
diovascular disease and type 1 diabetes.
Bovine milk naturally contains somatic cell, endogenous
proteases, and unwanted bacteria, which may hydrolyze
b-casein into peptides, including BCMs. Cieslinska et al.
(2007) detected BCM7 in unprocessed cow milk but this study
did not characterize whether somatic cells were present.
Therefore, the presence of BCM7 in bovine milk may have
been a result of microbial or somatic cell-derived enzyme
activity (EFSA, 2009) rather than BCM formation in the mam-
mary gland. However, Napoli et al. (2007) showed that BCM7
was not detected in milk from cows with mastitis, where con-
centration of somatic cells exceeds 500,000 per milliliter
(Ginn et al., 1985). So high levels of somatic cell may degrade
BCM7; but this needs further investigation. Similarly,
Cieslinska et al. (2012) investigated the presence of BCM7 in
bovine milk collected from healthy cows which did not indi-
cate any subclinical symptom of mastitis and showed that
BCM7 was detected in all milk samples with the highest
amount in A1 milk, followed by A1A2 milk and A2 milk. Sur-
prisingly, BCM7 was found in the milk containing the A1 vari-
ant but also in A2 variant-containing milk. However, the
authors did not characterize the number of bacterial cells, the
conditions and duration of storage of samples, or the presence
of plasmin, an endogenous protease present in milk. Conse-
quently, it is possible that the release of BCM7 may involve
hydrolysis by bacterial-derived enzymes or endogenous
enzymes of A1 b-casein to form BCM7. This research, how-
ever, still contradicts other studies that have not found BCM7
in milk of the A2 b-casein variant.
Findings in human milk may assist in our understanding of
the origin and fate of BCMs in bovine milk. For instance, Jar-
mo»owska et al. (2007) reported that beta-casomorphin 5
(BCM5) and BCM7 were found in human colostrums and
mature milk; the BCM content of the former being much
higher than that of the later. According to the authors, milk
samples were selected from healthy women and frozen imme-
diately after expression and stored at ¡70C; excluding the
possibility of formation of BCMs by somatic cell and bacterial
enzyme action. These findings indicate that BCMs may be
released from b-casein in the mammary gland by endogenous
enzyme activity (Koch et al., 1988). Endogenous enzyme
activity may also result in peptide formation during the manu-
facture of cheese and other fermented dairy products as will be
described in the following sections.
Cheese
Cheese is a dairy product that is a commonly consumed part
of the diet in Western countries, and is commonly produced
from bovine milk. Major steps in cheese manufacture include
Figure 2. Release of BCM7 b-casein variant (adapted from Woodford, 2009).
Table 1 BCMs released from bovine milk
Beta-casomorphins Structure References
BCM 4, b-CN f(60–63) Tyr-Pro-Phe-Pro EFSA (2009), Kaminski et al. (2007)
BCM 5, b-CN f(60–64) Tyr-Pro-Phe-Pro-Gly EFSA (2009), Kaminski et al. (2007)
BCM 6, b-CNf(60–65) Tyr-Pro-Phe-Pro-Gly-Pro Kaminski et al. (2007)
BCM 7, b-CN f(60–66) Tyr-Pro-Phe-Pro-Gly-Pro-Ile EFSA (2009), Kaminski et al. (2007)
BCM 8, b-CN f(60–67) Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro EFSA (2009), Kaminski et al. (2007)
BCM 9, b-CN f(60–68) Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn Saito et al. (2000)
BCM 10, b-CN f(60–69) Tyr-Pro-Phe-Pro-Gly-Pro-Ile-His-Asn-Ser Toelstede and Hofmann (2008)
BCM 11, b-CN f(60–70) Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn-Ser-Leu Kaminski et al. (2007)

































heat treatment of milk, coagulation with rennet and starter cul-
ture, separation of curd from whey, and ripening of curd to
produce the final cheese. Heat treatment of milk is commonly
done by pasteurization at 72C for 15 seconds (Hayaloglu
et al., 2010). Cheese studies that used milk heated at above
72C involving peptide profiles (Hougaard et al., 2010)
showed denaturation of whey protein, leading to the interac-
tion between whey protein and casein. High temperature pre-
treatment may significantly affect proteolysis of cheese during
ripening as well as its final flavor and texture (Benfeldt and
Słrensen, 2001). Protelolysis during ripening may involve the
formation of large peptides, some of which are subsequently
degraded into smaller peptides that may include pro-BCMs
and BCMs as well as free amino acids and aroma compounds
(Benfeldt and Słrensen, 2001).
Currently, only a few studies have investigated the forma-
tion of BCMs in cheese varieties (Sienkiewicz-Sz»apka et al.,
2009; De Noni and Cattaneo, 2010). In Brie cheese, BCM7
was found in the range 5 to 15 mg/g following treatments of
different ripening times by Jarmo»owska et al. (1999), whereas
De Noni and Cattaneo (2010) detected only 0.15 mg/g and
Sienkiewicz-Sz»apka et al. (2009) found 6.48 mg/g. BCM7
was found 0.01 to 0.11 mg/g in Gorgonzola, Gouda, Fontina,
and Cheddar (De Noni and Cattaneo, 2010). Similarly, Sien-
kiewicz-Sz»apka et al. (2009) quantified BCM7 in some
locally produced Polish mould cheeses (Brie and Rokpol) and
determined that levels were much higher than that of the semi-
hard cheeses they analyzed (Edamski, Gouda and Kasztelan).
The levels of BCM7 and other related BCMs reported in some
cheeses are shown in Table 2. In addition to BCM7, BCM5
was found in Brie, Rokpol, Edamski, Gouda, and Kasztelan
(Sienkiewicz-Sz»apka et al., 2009), BCM9 (Saito et al., 2000;
Toelstede and Hofmann, 2008) and BCM10 in Gouda (Toel-
stede and Hofmann, 2008) and BCM 11 in Caprino del Pie-
monte, an Italian goat cheese (Rizzello et al., 2005). In
contrast, Muehlenkamp and Warthesen (1996) reported that
BCM7 were not detected in Brie and Cheddar. According to
the authors, the absence of BCM7 in these products may be
due to (a) nonformation of BCMs from b-casein, (b) degrada-
tion of BCM7 during ripening, or (c) smaller amounts of
BCM7 than the minimum detectable level by RP-HPLC
(<2 mg/mL of cheese extract).
The formation of BCM7 in some cheeses is due to the
digestion of b-casein with starter culture derived enzymes. By
using a HPLC-MS/MS method, De Noni and Cattaneo (2010)
found 0.11 mg/g of BCM7 in Cheddar cheese. According to
Jarmolowska et al. (1999), the presence of BCM7 in cheese
does not originate from that originally present in milk, because
milk-derived peptides would be removed from the curd during
the drainage of whey. Cheddar cheese making commonly use
starter cultures which are a mixture of Lactococcus. lactic ssp.
cremoris and L. lactic ssp. lactic (Robinson, 1995). Muehlen-
kamp and Warthesen (1996) showed that enzymes derived
from L. lactic ssp. cremoris are capable of reducing the
amount of BCM7 found by 50% at pH 5.0 and 1.5% NaCl after
6–15 weeks; conditions which are similar to those in Cheddar
cheese making. Thus, the concentration of BCM7 in Cheddar
cheese at the beginning period of ripening may be higher than
Table 2 BCMs in cheeses
Cheese b-casomorphins Content (mg/g) References
Brie BCM7 5–15 Jarmolowska et al. (1999)
0.15 De Noni and Cattaneo (2010)
6.48 Sienkiewicz-Sz»apka et al. (2009)
BCM5 3.14 Sienkiewicz-Sz»apka et al. (2009)
Cheddar BCM7 0.11 De Noni and Cattaneo (2010)
BCM5 Not reported De Noni and Cattaneo (2010)
BCM9 Identified Singh et al. (1997)
Gorgonzola BCM7 0.01 De Noni and Cattaneo (2010)
BCM5 Not reported De Noni and Cattaneo (2010)
Fontina BCM7 0.04 De Noni and Cattaneo (2010)
BCM5 Not reported De Noni and Cattaneo (2010)
Gouda BCM7 0.06 Sienkiewicz-Sz»apka et al. (2009)
0.1 De Noni and Cattaneo (2010)
BCM5 0.05 Sienkiewicz-Sz»apka et al. (2009)
BCM9 Identified Saito et al. (2000); Toelstede and Hofmann (2008)
BCM10 Identified Toelstede and Hofmann (2008)
Rokpol BCM7 1.66 Sienkiewicz-Sz»apka et al. (2009)
BCM5 2.57 Sienkiewicz-Sz»apka et al. (2009)
Edamski BCM7 1 Sienkiewicz-Sz»apka et al. (2009)
BCM5 0.46 Sienkiewicz-Sz»apka et al. (2009)
Kasztelan BCM7 0.04 Sienkiewicz-Sz»apka et al. (2009)
BCM5 0.14 Sienkiewicz-Sz»apka et al. (2009)
Taleggio, Caprino and Grana Padano BCM7 No detected De Noni and Cattaneo (2010)
BCM5 Not reported De Noni and Cattaneo (2010)
BCM5 Not reported De Noni and Cattaneo (2010)

































that in the ripened cheese reported by De Noni and Cattaneo
(2010), since BCM7 may have been formed from b-casein on
the addition of starter culture, but degraded into even smaller
peptides during ripening.
As well as through starter cultures, there is potential for bio-
active peptides including BCMs to be formed by hydrolysis of
b-casein by endogenous proteases and nonstarter culture bac-
terial proteases from contaminated udder, pipes, and equip-
ment (EFSA, 2009). However, the endogenous protease
plasmin has been shown not to release BCMs (Gaucher et al.,
2008) and similarly the rennet enzymes used to coagulate milk
protein also do not liberate bioactive peptides (McSweeney,
2004); excluding these enzymes activities as sources of
BCMs. Hayaloglu et al. (2010) investigated the peptide profile
of Malatya cheese made from raw milk without addition of
starter culture. The authors demonstrated considerably higher
concentration of peptides but did not measure BCMs, although
they may have been present in this cheese. Hayaloglu et al.
(2010) compared to raw milk cheese to cheese made from pas-
teurized milk with added L. lactis ssp. lactis and S. Thermophi-
lus and suggested that the resultant peptides were as a result of
nonstarter culture derived enzyme-activity. However, to date,
there is no published paper investigating formation of BCMs
by nonstarter culture-derived proteases.
The presence of BCM7 in cheese may also be due to the
activity of enzymes derived from mould during ripening. The
level of BCM7 in Brie (Sienkiewicz-Sz»apka et al., 2009; De
Noni and Cattaneo, 2010) and Rokpol ripened with fungi and
lactic acid bacteria (LAB) (Sienkiewicz-Sz»apka et al., 2009)
was considerably higher than that in cheese ripened with only
LAB. Similarly, Jarmolowska et al. (1999) also observed a high
level of BCM7 in Brie. Consequently, the formation of BCM7
in Brie and Rokpol cheese may be due to proteolytic digestion
of protein by both enzymes derived from fungi (De Noni and
Cattaneo, 2010) and LAB (Jarmolowska et al., 1999).
The stability of BCM7 may depend on the type of enzymes
present in cheese. Haileselassie et al. (1999) investigated
potentially bioactive peptides including BCM7 in Cheddar
cheese extract with the addition of the enzyme, Neutrase iso-
lated from B. subtilis. BCM7 was identified but the amount
was not reported. However, no BCM7 was detected in sam-
ples: (a) prepared from the Cheddar cheese extract with added
Neutrase plus a crude extract of L. casei isolated from mild
Cheddar cheese or (b) the Cheddar cheese extract with added
Neutrase plus a peptidase isolated from Lactococcus lactic
and Asperillus oryzae. Haileselassie et al. (1999) suggested
that the presence of BCM7 in the cheddar cheese extract with
Neutrase was as a result of b-casein hydrolysis by the Neu-
trase. The absence of BCM7 in the two latter samples may
have been as a result of BCM7 hydrolysis by proteases to a
level lower than the threshold level of the analysis. Thus, the
formation and degradation of BCM7 may involve proteases
derived from bacteria used in the starter culture.
The characterization of BCM precursors (i.e. longer peptide
chains containing the BCM amino acid sequence) in cheese
may support our understanding of the steps involved in BCM
formation. In general, proteases digest b-casein into larger
peptides including BCM precursors, and subsequently some of
precursors are degraded into BCMs by specific peptidases.
One BCM precursor found in Crescenza (Smacchi and Gob-
betti, 1998) and in Cheddar and Jarlsberg cheese (Stepaniak
et al., 1995) after ripening for 8–10 days was b-CN f58-72
(Smacchi and Gobbetti, 1998). This peptide may be further
digested into BCM13 (b-CN f60-72) as reported by Jinsmaa
and Yoshikawa (1999) and other related BCMs if cheese is
aged for a longer period.
As previously described, the formation of BCM7 in cheese
depends on b-casein variants present in the milk used for pro-
ducing the cheese; A1 and B b-casein variants being those
most likely to contribute to release of BCM7. Most studies
above investigated BCM7 and other related BCMs in commer-
cial cheeses that were not characterized for the b-casein vari-
ant in the milk used, except for the study of De Noni and
Cattaneo (2010). According to De Noni and Cattaneo (2010),
A1, A2, and B variant of b-casein were detected in all cheese
samples, so it was unclear which of the variants contributed to
the occurrence of BCM7 following fermentation. For elucidat-
ing which variant(s) is (are) the source of BCM7 during cheese
making, it will be necessary to investigate the formation of
BCM7 and other related BCMs in cheese produced from milk
of single b-casein variants in future research.
Yoghurt
Yogurt is a popular dairy product usually fermented by two
lactic acid bacteria, L. delbrueckii ssp. bulgaricus and S. ther-
mophilus (Tamime and Robinson, 1999). Major steps in
yoghurt processing include thermal treatment, fermentation, and
chilled storage. In addition to inducing changes in pH and vis-
cosity, the yoghurt culture can hydrolyze the milk proteins into
peptides with bioactivity. A number of bioactive peptides have
been isolated from yoghurt, such as ACE-I peptides (Donkor
et al., 2007; Kunda et al., 2012) and antihypertensive peptides
(Schieber and Br€uckner, 2000; Muguerza et al., 2006; Kunda
et al., 2012). However, no study has reported on the formation
or degradation of BCMs in yoghurt. The lack of reliable infor-
mation about BCMs in yoghurt may be in part due to difficulty
in identification and quantification of the low levels of these
peptides within the complex yoghurt matrix (EFSA, 2009).
As reported by Donkor et al (2007), b-casein-derived pepti-
des were isolated from yoghurt inoculated with yoghurt starter
culture and probiotic organisms (L. casei L26, L. acidophilus
L10 and B. lactis B94). These peptides included different b-CN
fragments (b-CN f193-198, f25–29, f69–73 and f84–86) but nei-
ther BCMs nor precursors of BCM were identified. Similarly,
Schieber and Br€uckner (2000) identified 30 peptides in yoghurt
fermented with L. delbrueckii ssp. bulgaricus and S. salivarius
ssp. thermophilus, mainly produced from A1 b-casein. These
authors did observe two precursors of BCM, b-CN f57–68, and
b-CN f57–72, containing histidine at position 67 of the parent

































b-casein. This finding suggested that precursors of BCM are
more likely to be formed from A1 and B b-casein variant than
A2 b-casein (Schieber and Br€uckner, 2000).
According to Kunda et al. (2012), a large number of pepti-
des were formed from both A1 and A2 b-casein variants dur-
ing yoghurt manufacture, among which a peptide containing
the BCM7 sequence, namely b-CN f58–72 was identified. In
addition, some peptides identified in yoghurt were released
from only the A2 b-casein variant, namely b-CN f59–68 and
b-CN f59–70 and these peptides may be further degraded into
BCM13, BCM9, and BCM10, respectively. Furthermore, the
authors found b-CN f60–72 was liberated from A1 b-casein
variant, indicating that yoghurt starter cultures may hydrolyze
A1 b-casein variant into BCMs. Several di-peptides have been
also identified in yoghurt, such as b-CN f60–61 and b-CN
f62–63. Both di-peptides were released from A1 and A2
b-casein variants. As previously described in Figure 1, amino
acids at position 61 and 63 on the chain of parent b-casein are
proline residues. Therefore, this finding indicated that yoghurt
bacteria-derived enzymes are likely to digest the peptide bonds
between proline and other amino acid residues, leading to deg-
radation of BCMs. This degradation of BCMs during yoghurt
processing may involve the activity of X-prolyl dipeptidyl
aminopeptidase (PepX). PepX is derived from LAB and is spe-
cifically hydrolyzes peptide bonds between proline and other
residues (Gobbetti, 2002). Similarly, Sabeena Farvin et al.
(2010) identified peptide fragments in commercial yogurt
within 24 hours of production. Peptides detected included
fragments of as1, as1, k-casein, with a majority of fragments
from b-casein, from which BCM9 was released from A2
b-casein but BCM7 was not found. The formation of BCMs in
cheese processing suggests BCMs may be formed and then
degraded during yoghurt processing. Kunda et al. (2012) and
Sabeena Farvin et al. (2010) did not isolate and characterize
starter cultures present in the yoghurt they investigated, which
is a key factor influencing the production and degradation of
peptides, including the final BCMs content of the product.
Yogurt inoculated with a mixture of L. delbrueckii ssp. bul-
garicus and S. thermophilus was isolated and characterized by
De Noni and Cattaneo (2010) in a BCM7 study. The yoghurts
did not contain BCM7, although A1, A2, and B b-CN variants
were identified in yoghurts. The same results were reported by
Schieber and Br€uckner (2000) investigating yoghurt kept
21 days at 4C. Thus, it has been suggested that the mixture of
starter culture L. delbrueckii ssp. bulgaricus and S. thermophi-
lus is not capable of proteolysis of b-casein to form BCMs.
This finding was also supported by work on Taleggio cheese
using L. delbrueckii ssp. bulgaricus and S. thermophiles as
starter culture, that did not contain BCM7 (De Noni and Catta-
neo, 2010). However, both the yoghurt and Taleggio cheese
used for the analysis of BCM7 were kept for 30 days and
35 days, respectively (De Noni and Cattaneo, 2010). As
reported by Atlan et al. (1990) PepX is located in cytoplasm,
so these long periods of aging possibly resulted in cell lysis,
leading to release of PepX that during storage of yoghurt
degraded and BCMs formed. In addition, during fermentation,
the proteases associated with the cell wall of the starter culture
or contaminating bacteria can hydrolyze caseins into large
peptides and possibly even BCM7, which subsequently are
transported into the bacteria cell and then hydrolyzed into a
large number of smaller peptides, e.g., di and tri-peptides
(Nielsen et al., 2009). Consequently, L. delbrueckii ssp. bul-
garicus and S. thermophilus used for producing yoghurt may
digest b-casein into BCM7 and other related BCMs; however,
these may be subsequently degraded into smaller peptides.
The stability of BCMs in yoghurt may be influenced by the
symbiotic growth of L. delbrueckii ssp. bulgaricus and S. ther-
mophilus. It is well known that the growth of L. delbrueckii ssp.
bulgaricus and S. thermophilus is strongly related, because prod-
ucts released by each organism stimulate the growth of the other
(Tamime and Robinson, 1999). For instance, some peptides and
amino acid formed by L. delbrueckii ssp. bulgaricus stimulate
the growth of S. thermophilus (Courtin et al., 2002). Therefore,
BCMs may be released by L. delbrueckii ssp. bulgaricus prote-
ase activity and subsequently degraded by S. thermophilus, and
vice versa. Nevertheless, Gobbetti et al. (2000) have demon-
strated that only the strain of L. delbrueckii ssp. bulgaricus SS1,
when used for fermentation of yoghurt, produced several frac-
tions originating from b-CN such as b-CN f6–14, b-CN f7–14,
b-CN f73–82, b-CN f74–82, and b-CN f75–82 but no BCMs.
Similarly, Papadimitriou et al. (2007) identified b-CN f176–180
and b-CN f1–8 in sheep yoghurt inoculated with only L. del-
brueckii ssp. bulgaricus Y 10.13. It is unknown when and if
BCMs are released or degraded in yoghurt processing as using
starter cultures L. delbrueckii ssp. bulgaricus and S. thermophi-
lus but this needs further investigation.
IMPACT OF DAIRY PROCESSING ON FORMATION
AND DEGRADATION OF BETA-CASOMORPHINS
Effect of Thermal Treatment
Thermal treatment is an important step in dairy processes
from a food safety and quality point of view. In addition to
killing both spoilage and pathogenic bacteria, thermal treat-
ments result in the modification of the milk protein conforma-
tion that beneficially affects the texture and viscosity of
fermented dairy products (Krasaekoopt, 2003; Hattem et al.,
2011). In yoghurt production, secondary heating in addition to
pasteurization is commonly performed at 90–95C for five
minutes (EFSA, 2009) causing denaturation of whey proteins,
and promotion of the interaction between caseins and whey
proteins; particularly k-casein and b-lactoglobulin. The forma-
tion of this complex influences proteolysis during fermentation
(El-Zahar et al., 2003). Furthermore, heat treatments contrib-
ute to the breakdown of parent proteins to form lower molecu-
lar weight peptides (Gaucheron et al., 1999).
Formation of peptides from caseins is not only by enzy-
matic (Lotfi, 2004; Meltretter et al., 2008) but also through

































fragmentation of the protein backbone during heat treatment of
milk (Meltretter et al., 2008). Meltretter et al. (2008) identi-
fied five new peptides not present in the raw milk, after it was
heated at 120C for 30 minutes. Unknown peptides were iden-
tified by matrix-assisted laser desorption/ionization time of
flight mass spectrometry (MALDI-TOF-MS) at mass-to-
charge (m/z) ratios 974.4, 2218.7, 3730.1, 4297.8, and 4436.8
and they were reported to have originated from caseins. None
of the m/z values matched those of BCMs indicating that no
BCMs were formed by simply heating raw milk. During heat
treatment of milk at 120C for 30 minutes, enzymes are inacti-
vated and the pH of the milk is unlikely to change greatly,
therefore the formation of peptide by enzyme and acid hydro-
lysis can be excluded. On the other hand, during thermal treat-
ment of milk the Maillard reaction, which is a reaction
between a reducing sugar (lactose) with amino acids, may
form radicals that can attack the peptide bonds within the pro-
tein to cleave the bonds and yield new peptides (Meltretter
et al., 2008).
The formation of new peptides during heat treatment of
milk will depend on the thermal strength of peptide bonds of
b-casein. Gaucheron et al. (1999) reported the formation of
low molecular weight peptides in raw skim milk heated at
120C for 30 minutes. Ten peptides, not present in raw milk,
were identified; two of which were liberated from b-casein,
including b-CN f1–14 and b-CN f1–16 but neither BCMs nor
precursors of BCMs were found. According to the authors,
peptides released after heat treatment are mainly a result of the
hydrolysis of peptide bonds involving either aspartic acid
(Asp), asparagine (Asn), or glutamic acid (Glu) bound to any
other amino acid; bonds known to be more susceptible to
hydrolysis during heat treatment (Gaucheron et al., 1999).
Gaucher et al. (2008) found Asn containing peptide bonds
were also susceptible to thermally induced breakdown.
Gaucher et al. (2008) identify several pro-BCMs in UHT milk
stored for six months at 20C, namely; b-CN f54–68, b-CN
f54–69, b-CN f55–65, b-CN f55–68, and b-CN f57–68
derived from the action of the enzymes elastase and cathe-
psins. Peptides, b-CN f54–68, b-CN f55–68, and b-CN f57–
68, resulted from hydrolysis of a peptide bond involving Asn.
Therefore, it appears that peptide bonds containing Asn are
more susceptible to hydrolysis than those not containing this
amino acid residue during heat treatment of milk. Schieber
and Br€uckner (2000) also found b-CN f57–68 in yoghurt
which may have been a result of milk heat treatment which is
a common processing step in yogurt production.
Recently, the formation and stability of BCM7 in heated
milk has attracted attention of researchers (De Noni and Catta-
neo 2010; Cieslinska et al. 2012). De Noni and Cattaneo
(2010) were the first to measure BCM7 content in commercial
pasteurized, UHT, and in-bottle heat-treated milk. The authors
showed that BCM7 was not detected in these products, even
though the products contained A1 and B b-casein variants
which contain the BCM7 sequence. Similarly, Cieslinska et al.
(2012) quantified the content of BCM7 by ELISA in varieties
of milk containing pure A1, A2 and mixture of A1 and A2
b-casein variants after pasteurization (95C/20 minutes) and
sterilization (117C/5 minutes). BCM7 content tended to
decrease after heating of the milk but not due to the breaking
down the peptide bonds of BCM7 but because of the reaction
between lactose and amino acids residues of BCM7, which
reduced the binding affinity of the modified BCM7 to the anti-
body used in the ELISA assay, leading to underestimated
results for BCM7 levels (Cieslinska et al., 2012). Thus, ther-
mal treatment may modify the b-casein and influence forma-
tion of BCM7 in further processing of dairy products.
The previous thermal treatment history of the milk plays a
crucial role in proteolysis during subsequent fermentation and
aging of fermented dairy products (El-Zahar et al., 2004).
Hayaloglu et al. (2010) investigated the peptide profile of
Malatya cheese made from raw milk and from milk pasteur-
ized at 72C for 30 seconds. The authors suggested that pas-
teurization of milk results in a decrease in peptide content
during ripening, with considerably higher concentration of
peptides being reported in cheese made from raw milk than
from pasteurized milk; however, the actual peptides produced
were not identified. The release of peptides may be due pri-
marily to proteolysis by nonstarter bacteria-derived protease
activity in the raw milk as pasteurization of milk at 72C for
30 seconds inactivated nonstarter culture bacteria. In contrast,
Mendia et al. (2000) reported that the level of proteolysis,
mainly of b-casein, was higher in cheese made from pasteur-
ized ewe milk than that made from raw milk.. The action of
plasmin which is more active in milk that has been pasteurized
than in unheated milk may be the reason for the contrast in
results (Mendia et al., 2000; Benfeldt and Sørensen, 2001),
although plasmin will be inactivated upon severe heat treat-
ment of milk. Although a number of studies have investigated
the effect of thermal treatment of milk on proteolysis (Rynne
et al., 2004; Hayaloglu et al., 2010; Hougaard et al., 2010), its
effect on modification of protein, leading to formation of
BCMs in the final fermented dairy product is still unknown.
Effect of Fermentation Process
Fermentation is an extremely important step in the process-
ing of milk into cheese and yoghurt. In addition to a drop in
pH, the fermentation process causes a series of changes in
chemical composition of milk resulting from proteolysis, gly-
colysis, and lipolysis. These reactions are dependent on the
type of starter culture, incubation temperature and time, and
maturation time.
The choice of starter culture is a crucial factor in determin-
ing the attributes of fermented dairy products. During fermen-
tation, different strains of starter culture can release different
bioactive peptides from milk protein, including BCMs liber-
ated from b-caseins (Table 3). Some BCMs isolated from
cheeses have been described in Table 2; however, these stud-
ies did not characterize the starter cultures used for producing

































the cheeses. As previously described, the use of L. casei L26,
L. acidophilus L10, and B. lactis B94, for producing probiotic
yoghurt (Donkor et al., 2007) and L. delbrueckii ssp. bulgari-
cus and S. salivarius ssp. thermophilus for fermentation of tra-
ditional yoghurt (Schieber and Br€uckner, 2000; De Noni and
Cattaneo, 2010) does not result in the formation of BCM7 and
other related BCMs. According to Atlan et al. (1990) and
Meyer and Jordi (1987), a mixture of starter cultures, L. del-
brueckii ssp. bulgaricus and S. thermophilus used for tradi-
tional yoghurt making contains a high level of PepX that may
degrade proline-rich BCMs into a large number of smaller
peptides. Meyer and Jordi (1987) reported that the pH opti-
mum of PepX isolated from S. thermophilus was in the range
of 6.5–8.2 and that this enzyme is inactivated at pH below 5.0.
For PepX isolated L. delbrueckii ssp. bulgaricus optimal con-
ditions were pH 7.0 and 50C (Atlan et al., 1990). Yoghurt fer-
mentation also involves a drop in pH from 6.8 to 6.3 during
first stage of fermentation and if BCM7 is released at this
stage, it may be degraded by PepX. Consequently, when
BCM7 is formed or degraded in yoghurt inoculated with
L. delbrueckii ssp. bulgaricus and S. thermophilus remains
unknown.
In addition to type of starter culture, the pH at which the
fermentation stops is a key factor affecting proteolysis subse-
quent during cold storage. In fermented milk manufacture, fer-
mentation commonly ends at pH 3.5–4.6 before subsequent
cold storage. According to Nielsen et al. (2009), milk inocu-
lated with L. lactis strains and L. helviticus strains fermented
to pH 4.6 and 4.3 resulted in large peptides being released
from b-casein after 7-day cold storage, but no BCMs. The
authors also observed no change in peptide profile during stor-
age for milk inoculated with S. thermophilus fermented to pH
4.6 and 4.3. This study indicated that protease derived from S.
thermophilus was not active during cold storage. In another
study, Paul and Somkuti (2009) showed that peptides were
slightly degraded by S. thermophilus and moderately hydro-
lyzed by L. delbrueckii spp. bulgaricus at pH 4.5 indicating
that any BCMs formed during yogurt fermentation might also
be slightly degraded at pH 4.5 during storage. Currently, there
is very little published research on the effect of pH, especially
a pH of 3.5, on the release or degradation during cold storage
of BCMs in yoghurt inoculated with L. delbrueckii ssp. bul-
garicus and S. thermophilus.
Effect of Cross Linking
In dairy technology, it is well-known that heat treatment
(85–90C for five minutes) increases the viscosity of yoghurt
due to the interaction between k-casein and whey protein by
di-sulphide bonding. Due to the lack of cysteine in b-casein,
inter/intra-molecular disulphide bonds formation during heat
treatment are not possible for this protein. However, modifica-
tion of b-casein can be performed by enzymatic covalent
cross-linking (Monogioudi et al., 2009) via tyrosine, lysine,
and glutamine residues through the addition of tyrosinase and
transglutaminase (TGase) (Monogioudi et al., 2009).
TGase affects the texture and proteolysis of yoghurt (Yuk-
sel and Erdem, 2010; Sanli et al 2011). Yuksel and Erdem
(2010) reported that peptide content of yoghurt decreases
when TGase is added to the milk, but there was no difference
in the peptide profile between TGase-treated and untreated
milk. Furthermore, peptide content in milk treated with TGase
that was still active during fermentation was less than that in
milk treated with Tgase that had been inactivated during fer-
mentation. The formation of inter-molecular cross-linking dur-
ing fermentation of yoghurt is related to the increase in lactic
acid that leads to a decrease in stability of casein micelles
(Yuksel and Erdem, 2010). As described in Table 1, BCMs
contain tyrosine residues that have the potential to form
enzyme-catalyzed cross-linking, therefore, treatment of milk
with cross-linking enzymes may reduce the production of
BCMs from b-casein.
METHODS FOR IDENTIFICATION AND
QUANTIFICATION OF BETA-CASOMORPHINS
Milk and dairy products are complex matrices, in which
proteins, lactose, and lipids can interfere with separation and
detection of target peptides, leading to erroneous quantitative
and qualitative results. Reversed-phase high performance
Table 3 BCMs released by different bacteria
b-casomorphins Starter culture Origin References
b-casomorphin 4 A mutant of Lactobacillus helveticus Bovine milk Matar and Goulet (1996)
b-casomorphin 5 A mixture of Lactococcus lactis subsp. lactis and
Streptococcus thermophilusa
Bovine milk Sienkiewicz-Sz»apka et al. (2009)
b-casomorphin 7 A mixture of Streptococcus salivarius ssp. thermophilus,
Lc. lactis ssp. lactis and Lc. lactis ssp. cremorisb
Bovine milk De Noni and Cattaneo (2010)
Sienkiewicz-Sz»apka et al. (2009)
Jarmolowska et al. (1999)
b-casomorphin 9 A mixture of Lactococcus lactis spp. Lactis and
Leuconostoc mesenteroides ssp. dextranicum
Bovine milk Gomez-Ruiz et al. (2004)
aStarter culture used for Gouda cheese making (Messens et al., 1999).
bStarter culture used for Brie cheese making (Lefier et al., 2000).




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































liquid chromatography (RP-HPLC) has been used widely in
separation of peptides and amino acids. For example, RP-
HPLC-UV (Muehlenkamp and Warthesen, 1996) and ion-
exchange chromatography (Jarmolowska et al., 1999) have
been used for the separation and quantification of BCM7 pres-
ent in cheese while HPLC-UV has been also used for deter-
mining BCM7 content in human milk (Jarmo»owska et al.,
2007). A limitation of RP-HPLC-UV is that peptides with sim-
ilar physico-chemical and spectrophotometric absorption prop-
erties can co-elute with BCMs, increasing the absorption
values (Muehlenkamp and Warthesen, 1996; Sienkiewicz-
Sz»apka et al., 2009), resulting in an overestimation of the
BCM7 content (Cass et al., 2008). In addition, methods
employing UV-Vis adsorption may lack the sensitivity
required to quantify low levels of BCM7 found in some dairy
products. The limit of quantification for BCM7 analyzed by
RP-HPLC-UV is approximately 2 mg/mL of cheese extract
making accurate quantification often not possible (Muehlen-
kamp and Warthesen, 1996). Despite these deficiencies, RP-
HPLC-UV is a well-established, relatively cheap, and user-
friendly analytical technique. These characteristics all contrib-
ute to make the technique very popular among others.
Currently, HPLC coupled with mass spectrometry (MS)
represents “the-state-of-the-art” method for identification and
quantification of peptides in complex matrices such as dairy
product extracts. Different mass spectrometry techniques such
as tandem mass spectrometry (MS/MS), quadrupole ion-trap
mass spectrometry (QIT-MS), and time of flight mass spec-
trometry (TOF-MS) have been applied successfully to assess
BCMs content in dairy products (Table 4). Each technique has
its own and unique advantages. The selectivity and sensitivity
of tandem mass spectrometry, especially when operated in
multiple reaction monitoring (MRM) mode, allows accurate
quantification of BCM5 and BCM7 at low levels (low mg/g) in
the presence of multiple co-eluting interferences. For example,
using LC-MS/MS, Haileselassie et al. (1999) identified several
potentially bioactive peptides, including BCM7, from an
enzyme-modified Cheddar cheese (EMC) prepared using a
neutral protease produced from B. subtilis. Using LC-MS, Riz-
zello et al. (2005) analyzed the water-soluble extracts of an
Italian goat cheese. BCM9 was identified in the extract. For-
mation of BCM7 following 10–60 minutes digestion of milk
with pepsin at pH 2.0 and b-casein degradation have also been
monitored using LC-MS (Schmelzer et al., 2007). More
recently, applications of HPLC-MS/MS for quantifying
BCM5 and BCM7 in dairy products (De Noni, 2008; De Noni
and Cattaneo, 2010) have been also reported. By using HPLC-
MS/MS, De Noni and Cattaneo (2010) quantitatively deter-
mined BCM5 and BCM7 in cheese, milk, fermented milk,
infant powder, and extracts of these products after in vitro sim-
ulated gastro-intestinal digestion. The authors showed that the
level of BCM7 that could be detected was as low as 0.01 mg/g.
Quadrupole ion trap mass spectrometry features multiple
tandem MS spectra (MSn), allowing, to some extent, structural
elucidation of unknown peptides. In a similar fashion to
tandem mass spectrometry, QIT-MS can be also used for quan-
titative assessment of BCM5 and BCM7 in single reaction
monitoring (SRM) mode. For example Juan-Garcia et al.
(2009) examined BCMs in cheese and milk using a nanoelec-
trospray quadrupole ion-trap mass spectrometer providing a
fast and easy means of analysis of these compounds in differ-
ent matrices. The main fragmentation pathways for BCMs and
structures for the major fragment ions that were recorded in
the MSn spectra, were also reported.
Time of flight mass spectrometry (TOF-MS), being a high
accuracy and high resolving power mass spectrometry tech-
nique, is of particular value for confirmation and when
unknown compounds need to be unequivocally identified in
complex matrices. This is usually achieved by combining ele-
mental formula information (i.e. CxHyOzNj. . .) from high
mass accuracy experiments with structural information from
fragmentation experiments. For example, using HPLC TOF-
MS, Toelstede et al. (2008) found BCM9 and BCM10 in the
water-soluble extract of a matured Gouda cheese. The possi-
bility of interfacing a matrix-assisted laser desorption ion
source (MALDI) to a TOF-MS allowed Cass et al. (2008) to
analyze opioid-derived exogenous or endogenous peptides in
urines of children with autism, and found that peaks previously
analyzed by HPLC-UV were erroneously identified as opioid
peptides. Hence the need of high resolution for identification
and confirmation work. Righetti et al. (1997) confirmed the
identity of opioid peptides by N-terminal sequencing followed
by MALDI-TOF mass spectrometry.
One alternative method for BCMs determination is ELISA
(Sienkiewicz-Sz»apka et al., 2009; Cieslinska et al., 2012).
Using ELISA, levels of BCM7 and BCM5 in cheese as low as
0.04 and 0.05 mg/g, respectively, could be accurately quanti-
fied. However, heat treatment of milk may modify the confor-
mation of BCM7 by interaction between lactose and amino
acid residues, leading to reduction in the binding affinity of
the modified BCM7 to the antibody and underestimation of
the BCM level (Cieslinska et al., 2012). This may be a reason
why Cieslinska et al. (2012) observed the decrease of BCM7
content when determined by ELISA during heat treatment of
milk.
Thus, HPLC coupled to different ranges of mass spectrome-
try technologies is a suitable method for quantifying BCMs in
complex dairy matrices at low level as well as for confirmation
and identification of unknown peptides in the same matrices.
The possibility to extend the application of HPLC-MS to
determine BCMs content in biological fluids such as urine
does exist (Cass et al., 2008) as this technique has been proven
rather flexible, accommodating the analysis of a wide range of
matrices.
CONCLUSION
BCM is a group of opioid peptides released from b-casein
by proteolysis, among which BCM7 is a peptide released from

































b-casein variants containing histidine residue at position 67
(b-casein A1 and B variants). Consumption of milk containing
variant A1 and B b-casein may increase the risk of human dis-
ease such as type 1 diabetes and heart disease but an important
precursor to clinical studies is the an understanding of the con-
ditions that cause BCM formation and degradation. BCMs
may be formed in all fermented dairy products, cheese, and
yoghurt, but may be degraded during processing so as not
detectable in the product as consumed. Processing factors that
might affect the formation and/or degradation of BCMs
include heat treatment, fermentation, ripening, and cold stor-
age. Due to the lack of knowledge on the presence of BCM7
and other related BCMs in fermented milks, especially yoghurt,
it is now necessary to further study the effects of combinations
of processing factors on the formation and/or degradation of
BCM7 and other related BCMs in these popular products.
Whether BCMs do form in yoghurt and the amount of BCM
forming or degrading at different processing steps needs further
investigation and possibly will depend on the heat treatment
and fermentation process used, but it remains an intriguing
unknown. The application of analytical methods employing tan-
dem mass spectrometry or high resolution mass spectrometry is
strongly recommended to confidently identify and accurately
quantify BCMs in complex dairy product matrices.
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